GSK Stock Drops 41% in Volume but Ranks 537th in Market as Nucala Approval Marks Major COPD Treatment Milestone

On June 23, 2025, GSK's trading volume reached 1.85 billion, a 41% decrease from the previous day, ranking 537th in the day's stock market. GSK's stock price increased by 0.50%.

GSK's latest approval for Nucala as an add-on maintenance therapy for adults with inadequately controlled COPD and an eosinophilic phenotype marks a significant milestone. This approval addresses an unmet need in the treatment of COPD, a condition that affects approximately 14.2 million U.S. adults and is the fourth leading cause of death worldwide. The approval is part of GSK's broader strategy to redefine COPD treatment by introducing precision biologics to a field that has lagged for decades.

Nucala, which has been approved for various IL-5 mediated conditions since its initial FDA approval for severe asthma in November 2015, is now the only approved biologic for COPD patients with blood eosinophil counts as low as 150 cells/μL. This captures roughly 70% of inadequately controlled COPD patients on triple therapy, representing over a million potential patients in the U.S. alone.

GSK's vision for COPD treatment involves deconstructing the disease into its underlying mechanisms and addressing adherence challenges. Nucala's once-monthly schedule offers a convenience advantage over competitors, and GSK is developing depemokimab, a long-acting biologic that could be administered just twice a year. This approach aims to enable earlier treatment before the disease becomes severe, ultimately redefining COPD treatment by intervening at a much earlier stage.